

REMARKS

The specification has been amended to incorporate sequence identifiers in compliance with the Sequence Rules. A substitute sequence listing (paper and computer readable copy) and the required statements accompany this response.

Claim 4 has been cancelled without prejudice. Claims 1-3 and 5-9 have been amended to comply with the Election set forth below. Claims 5-9 have been amended to properly set forth antecedent basis. Support for the claims can be found throughout the specification as filed. For example, support can be found in the sequence listing and consensus sequences disclosed and described in the specification. No new matter is believed to have been introduced.

RESTRICTION REQUIREMENT

The Examiner alleges that the Claims encompass the following inventions:

Groups I-VI, claim(s) 1-12 and 19-23 (all in part), drawn to a polypeptide of SEQ ID NO: 1-6 and a hybrid molecule derived from SEQ ID NO:1-6.

Groups VII-XII, claims 13 and 24-25 (all in part), drawn to a method of treating or diagnosing Alzheimer's or a neurodegenerative disease using SEQ ID NO:1-6 or a hybrid molecule derived from SEQ ID NO:1-6.

Groups XIII-XVIII, claims 14-18 (all in part), drawn to a nucleic acid, vector, host cell for SEQ ID NO:1-6.

Groups XIX-XXIV, claim 26 (all in part), drawn to an anti-idiotype antibody binding to SEQ ID NO:1-6.

In addition, the Examiner indicates that should Applicants elect the invention of group I, that a further species election as set forth below is required:

i. If Group I is elected, Applicant is required under PCT Rule 13.2 to elect a single disclosed molecular embodiment of the integer selected from A) 1-20, B) 1-15, C) 1-10 or D) 1-5 as recited in claims 1-2, and 5-7 for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

ELECTION

Applicants elect the invention of Group V, claim 1-12 and 19-20 drawn to a polypeptide of SEQ ID NO:5. Claims 1, 2, and 3 have been amended to be consistent with this election. Subject matter cancelled from any claim is not disclaimed for any purpose and Applicants reserve the right to prosecute such subject matter in any divisional, continuation or continuation-in-part application.

For at least the foregoing, the Applicant submits that the claimed invention is patentable and request reconsideration and notice of such allowable subject matter.

The Director is authorized to charge any required fee or credit any overpayment to Deposit Account Number 50-4586, please reference the attorney docket number above.

The Examiner is invited to contact the undersigned at the below-listed telephone number, if it is believed that prosecution of this application may be assisted thereby.

Respectfully submitted,

GAVRILOVICH, DODD & LINDSEY LLP

Date: March 6, 2009

By: /Joseph R. Baker, Jr./
Joseph R. Baker, Jr.
Registration No. 40,900

4660 La Jolla Village Drive, Suite 750
San Diego, California 92122
(858) 458-3607 (Main)
(858) 458-9986 (Fax)